Tonix Pharmaceuticals [TNXP] - Last Close: $2.44
Tonix Pharma's newest patent could put the company in an excellent position.
The clinical-stage biopharma stock announced this morning that it has received a US patent for its TNX-801 smallpox/monkeypox vaccine entitled "Synthetic Chimeric Poxviruses" from the US Patent & Trademark office.
The patent covers claims to develop the company's TNX-801 vaccine for the protection against monkeypox, smallpox and for the company's Recombinant Pox Virus platform for the protection against other pathogens, including SARS-CoV-2. Tonix will have US market exclusivity until 2037.
TNXP is trading actively with a 26.2% gain.
The news comes as Monkeypox fears continue to rise in the US and Europe. Tonix could be in key position to take advantage of the hysteria if its vaccine proves safe and effective.
Our Take: Monkeypox could be a boom for Tonix, but does this company have what it takes to become the next Moderna? We're not sold. Trade smart and don't get caught up in the hype.